文献速递神经免疫

多发性硬化疾病修正治疗药物相关不良事件:一项多地区基于人群的研究

Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study.
PubMed 文献 · Neurology · 2024-01-05

该研究利用加拿大4省关联行政健康数据,纳入35894例多发性硬化患者,评估疾病修正治疗药物(DMD)与感染相关住院、就诊及15类新发不良事件的关联。多数DMD与感染相关住院风险降低42%-61%相关,但部分DMD感染相关就诊风险增加10%-33%;多数新发不良事件风险升高涉及第二代DMD,如阿仑单抗甲状腺疾病HR 19.42(95%CI 9.29-36.51)。

要点

  • 多数DMD与感染相关住院风险降低42%-61%相关,但部分DMD感染相关就诊风险增加10%-33%。
  • 阿仑单抗甲状腺疾病风险最高(HR 19.42,95%CI 9.29-36.51)。
  • 芬戈莫德与脑血管病(aHR 2.04)和缺血性心脏病(aHR 1.64)风险升高相关。

核心结论

  • 研究提供了多种DMD在真实世界中的广泛安全性特征,结果补充了短期临床试验的发现,并为临床实践中DMD的风险获益评估提供新见解。
  • 研究结果强调持续需要针对多发性硬化DMD的长期、独立安全性研究。

研究设计与样本

  • 多地区基于人群研究,利用加拿大4省关联行政健康数据识别多发性硬化患者。
  • 共纳入35894例多发性硬化患者,随访至 emigration、死亡或2017年12月31日中最早发生者。
  • 采用复发事件比例均值模型分析DMD暴露与感染相关住院和就诊的关联,采用分层多变量Cox比例风险模型分析DMD暴露与15类新发不良事件的关联。

主要发现

  • 几乎所有DMD与感染相关住院风险降低42%-61%相关,但部分DMD感染相关就诊风险增加10%-33%。
  • 阿仑单抗与甲状腺疾病风险升高相关(HR 19.42,95%CI 9.29-36.51),高血压风险升高(HR 4.96,95%CI 1.78-13.84),心血管疾病风险升高(HR 3.72,95%CI 2.12-6.53)。
  • 那他珠单抗最高风险为心血管疾病(aHR 1.61,95%CI 1.24-2.10)。
  • 芬戈莫德与脑血管病风险升高相关(aHR 2.04,95%CI 1.27-3.30),缺血性心脏病风险升高(aHR 1.64,95%CI 1.10-2.44),高血压风险升高(aHR 1.73,95%CI 1.30-2.31)。
  • 特立氟胺与甲状腺疾病风险升高相关(aHR 2.30,95%CI 1.11-4.74),慢性肝病风险升高(aHR 1.94,95%CI 1.19-3.18),高血压风险升高(aHR 1.76,95%CI 1.32-2.37),高脂血症风险升高(aHR 1.61,95%CI 1.07-2.44)。

关键数值与推荐

  • 该研究提供III级证据:对于多发性硬化患者,DMD暴露降低感染相关住院风险,但部分DMD增加感染相关就诊和新发不良事件风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: It is not possible to fully establish the safety of a disease-modifying drug (DMD) for multiple sclerosis (MS) from randomized controlled trials as only very common adverse events occurring over the short-term can be captured, and the quality of reporting has been variable. We examined the relationship between the DMDs for MS and potential adverse events in a multiregion population-based study. METHODS: We identified people with MS using linked administrative health data from 4 Canadian provinces. MS cases were followed from the most recent of first MS or related demyelinating disease event on January 1, 1996, until the earliest of emigration, death, or December 31, 2017. DMD exposure primarily comprised β-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, and alemtuzumab. We examined associations between DMD exposure and infection-related hospitalizations and physician visits using recurrent events proportional means models and between DMD exposure and 15 broad categories of incident adverse events using stratified multivariate Cox proportional hazard models. RESULTS: We identified 35,894 people with MS. While virtually all DMDs were associated with a 42%-61% lower risk of infection-related hospitalizations, there was a modest increase in infection-related physician visits by 10%-33% for select DMDs. For incident adverse events, most elevated risks involved a second-generation DMD, with alemtuzumab's hazard of thyroid disorders being 19.42 (95% CI 9.29-36.51), hypertension 4.96 (95% CI 1.78-13.84), and cardiovascular disease 3.72 (95% CI 2.12-6.53). Natalizumab's highest risk was for cardiovascular disease (adjusted hazard ratio [aHR] 1.61; 95% CI 1.24-2.10). For the oral DMDs, fingolimod was associated with higher hazards of cerebrovascular (aHR 2.04; 95% CI 1.27-3.30) and ischemic heart diseases (aHR 1.64; 95% CI 1.10-2.44) and hypertension (aHR 1.73; 95% CI 1.30-2.31); teriflunomide with higher hazards of thyroid disorders (aHR 2.30; 95% CI 1.11-4.74), chronic liver disease (aHR 1.94; 95% CI 1.19-3.18), hypertension (aHR 1.76; 95% CI 1.32-2.37), and hyperlipidemia (aHR 1.61; 95% CI 1.07-2.44); and from complementary analyses (in 1 province), dimethyl fumarate with acute liver injury (aHR 6.55; 95% CI 1.96-21.87). DISCUSSION: Our study provides an extensive safety profile of several different DMDs used to treat MS in the real-world setting. Our findings not only complement those observed in short-term clinical trials but also provide new insights that help inform the risk-benefit profile of the DMDs used to treat MS in clinical practice. The results of this study highlight the continued need for long-term, independent safety studies of the DMDs used to treat MS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with MS, while DMD exposure reduces the risk of infection-related hospitalizations, there are increased risks of infection-related physician visits and incident adverse events for select DMDs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ng HS, Zhu F, Zhao Y, et al. Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study. Neurology. 2024. PMID: 38181306. doi:10.1212/WNL.0000000000208006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。